Eur Rev Med Pharmacol Sci 2021; 25 (12): 4422-4425
DOI: 10.26355/eurrev_202106_26154

Post COVID syndrome: a new challenge for medicine

U. Tirelli, R. Taibi, S. Chirumbolo

Tirelli Medical Group, Pordenone (PN), Italy. salvatore.chirumbolo@univr.it

The huge concern raised by SARS-CoV2 pandemic about public health management and social impact is still under debate, particularly because COVID-19 may affect infected people much longer than expected from a typical air-borne viral disease. The scientific community is actually wondering about the etiopathogenesis and clinical development of this “post-COVID” complex symptomatology, very close to symptoms typically observed in chronic fatigue syndrome, so recently named as “post-acute sequelae of COVID-19 (PASC)”. This commentary tries to focus on the most recent news about this issue.

Free PDF Download

To cite this article

U. Tirelli, R. Taibi, S. Chirumbolo
Post COVID syndrome: a new challenge for medicine

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 12
Pages: 4422-4425
DOI: 10.26355/eurrev_202106_26154

Keywords Related articles:

  1. Post-COVID pulmonary fibrosis: therapeutic efficacy using with mesenchymal stem cells – How the lung heals
  2. Thromboembolic involvement and its possible pathogenesis in COVID-19 mortality: lesson from post-mortem reports
  3. Diabetes and COVID-19: a major challenge in pandemic period?
  4. Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19
  5. Web-mediated counseling to counteract the emotional impact of COVID-19 for women with interstitial cystitis/bladder pain syndrome